NasdaqGS - Nasdaq Real Time Price USD

Twist Bioscience Corporation (TWST)

Compare
46.46 +1.17 (+2.58%)
At close: September 24 at 4:00 PM EDT
Loading Chart for TWST
DELL
  • Previous Close 45.29
  • Open 45.00
  • Bid 46.45 x 300
  • Ask 46.54 x 400
  • Day's Range 44.99 - 46.83
  • 52 Week Range 14.42 - 60.90
  • Volume 407,885
  • Avg. Volume 945,546
  • Market Cap (intraday) 2.722B
  • Beta (5Y Monthly) 1.76
  • PE Ratio (TTM) --
  • EPS (TTM) -3.82
  • Earnings Date Nov 15, 2024 - Nov 19, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 53.09

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

www.twistbioscience.com

919

Full Time Employees

September 30

Fiscal Year Ends

Recent News: TWST

View More

Performance Overview: TWST

Trailing total returns as of 9/24/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

TWST
26.04%
S&P 500
20.19%

1-Year Return

TWST
128.42%
S&P 500
32.70%

3-Year Return

TWST
61.63%
S&P 500
28.86%

5-Year Return

TWST
71.50%
S&P 500
91.62%

Compare To: TWST

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: TWST

View More

Valuation Measures

Annual
As of 9/24/2024
  • Market Cap

    2.72B

  • Enterprise Value

    2.52B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    9.08

  • Price/Book (mrq)

    5.55

  • Enterprise Value/Revenue

    8.54

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -74.63%

  • Return on Assets (ttm)

    -16.39%

  • Return on Equity (ttm)

    -38.36%

  • Revenue (ttm)

    295.21M

  • Net Income Avi to Common (ttm)

    -220.31M

  • Diluted EPS (ttm)

    -3.82

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    289.42M

  • Total Debt/Equity (mrq)

    17.75%

  • Levered Free Cash Flow (ttm)

    -25.09M

Research Analysis: TWST

View More

Company Insights: TWST

Research Reports: TWST

View More

People Also Watch